Latest news with #XiamenAmoytopBiotech
Yahoo
27-05-2025
- Business
- Yahoo
Global Market's Trio Of Value Stocks Trading Below Estimated Worth
In the midst of recent global market volatility, spurred by tariff threats and fluctuating Treasury yields, investors are increasingly seeking opportunities to capitalize on stocks that may be trading below their intrinsic value. Identifying undervalued stocks can be particularly appealing in such an environment, as these equities often present potential for growth when market conditions stabilize or improve. Name Current Price Fair Value (Est) Discount (Est) Pansoft (SZSE:300996) CN¥14.23 CN¥28.33 49.8% Xiamen Amoytop Biotech (SHSE:688278) CN¥77.56 CN¥153.79 49.6% Fuji (TSE:6134) ¥2254.00 ¥4466.70 49.5% Shenzhen Yinghe Technology (SZSE:300457) CN¥17.28 CN¥34.49 49.9% adidas (XTRA:ADS) €218.70 €433.38 49.5% Clemondo Group (OM:CLEM) SEK10.70 SEK21.24 49.6% TLB (KOSDAQ:A356860) ₩17600.00 ₩34900.33 49.6% BalnibarbiLtd (TSE:3418) ¥1162.00 ¥2305.50 49.6% Nexstim (HLSE:NXTMH) €7.86 €15.69 49.9% Northern Data (DB:NB2) €24.78 €49.42 49.9% Click here to see the full list of 520 stocks from our Undervalued Global Stocks Based On Cash Flows screener. Let's dive into some prime choices out of the screener. Overview: Xiamen Amoytop Biotech Co., Ltd. focuses on the research, development, production, and sale of recombinant protein drugs in China with a market cap of CN¥30.42 billion. Operations: The company generates revenue primarily from its biologics segment, amounting to CN¥2.95 billion. Estimated Discount To Fair Value: 49.6% Xiamen Amoytop Biotech is trading at CN¥77.56, significantly below its estimated fair value of CN¥153.79, suggesting it may be undervalued based on cash flows. The company's earnings grew by 46.8% last year and are forecast to grow 28.5% annually, outpacing the market's growth rate. Recent transactions include a 5.7% stake acquisition by Tibet Trust Corporation for CNY 1.3 billion, highlighting investor interest amidst robust financial performance and growth prospects. In light of our recent growth report, it seems possible that Xiamen Amoytop Biotech's financial performance will exceed current levels. Take a closer look at Xiamen Amoytop Biotech's balance sheet health here in our report. Overview: Visional, Inc., along with its subsidiaries, offers human resources platform solutions in Japan and has a market cap of approximately ¥364.20 billion. Operations: The company's revenue is primarily derived from its HR Tech segment, which generated ¥69.50 billion, and its Incubation segment, contributing ¥2.10 billion. Estimated Discount To Fair Value: 43.7% Visional is trading at ¥9,211, considerably below its estimated fair value of ¥16,356.88, indicating potential undervaluation based on cash flows. Earnings are projected to grow at 14.7% annually, surpassing the JP market's growth rate of 7.6%. Revenue is expected to increase by 12.3% per year, also outpacing market averages. The company's return on equity is forecasted to reach a high level of 22.8% within three years, enhancing its investment appeal. Upon reviewing our latest growth report, Visional's projected financial performance appears quite optimistic. Dive into the specifics of Visional here with our thorough financial health report. Overview: KOSÉ Corporation is a company that manufactures and sells cosmetics and cosmetology products both in Japan and internationally, with a market cap of ¥313.40 billion. Operations: The company's revenue is primarily derived from its Cosmetics Business, which accounts for ¥256.70 billion, followed by Cosmetaries at ¥64.72 billion. Estimated Discount To Fair Value: 38.5% KOSÉ is trading at ¥5,566, significantly below its estimated fair value of ¥9,055.82. This undervaluation is highlighted by a forecasted annual earnings growth rate of 20.3%, outpacing the broader JP market's 7.6%. However, profit margins have decreased to 1.8% from last year's 4.7%, and the dividend yield of 2.52% isn't well covered by earnings or cash flows, presenting some challenges despite its attractive valuation based on cash flows. The analysis detailed in our KOSÉ growth report hints at robust future financial performance. Get an in-depth perspective on KOSÉ's balance sheet by reading our health report here. Click this link to deep-dive into the 520 companies within our Undervalued Global Stocks Based On Cash Flows screener. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:688278 TSE:4194 and TSE:4922. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-04-2025
- Business
- Yahoo
Asian Stocks Trading Below Estimated Value In April 2025
As of April 2025, Asian markets are navigating a landscape marked by easing trade tensions and cautious optimism, with China and Japan showing resilience amid global economic uncertainties. In this context, identifying undervalued stocks becomes crucial for investors seeking opportunities in Asia's diverse markets, where potential value can be unlocked through careful analysis of fundamentals and market positioning. Name Current Price Fair Value (Est) Discount (Est) Xiamen Amoytop Biotech (SHSE:688278) CN¥74.29 CN¥144.77 48.7% BYD Electronic (International) (SEHK:285) HK$31.80 HK$63.03 49.5% Alexander Marine (TWSE:8478) NT$142.50 NT$280.32 49.2% Zhende Medical (SHSE:603301) CN¥19.33 CN¥37.64 48.6% Members (TSE:2130) ¥1137.00 ¥2211.77 48.6% Rakus (TSE:3923) ¥2194.50 ¥4296.95 48.9% Beijing Zhong Ke San Huan High-Tech (SZSE:000970) CN¥10.51 CN¥20.78 49.4% BalnibarbiLtd (TSE:3418) ¥1152.00 ¥2223.40 48.2% Swire Properties (SEHK:1972) HK$16.82 HK$32.75 48.6% Yuhan (KOSE:A000100) ₩113000.00 ₩219128.89 48.4% Click here to see the full list of 263 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Here we highlight a subset of our preferred stocks from the screener. Overview: PharmaResearch Co., Ltd., along with its subsidiaries, is a biopharmaceutical company operating mainly in South Korea, with a market capitalization of approximately ₩3.91 trillion. Operations: The company generates revenue primarily from its Pharmaceuticals segment, amounting to approximately ₩350.12 billion. Estimated Discount To Fair Value: 24.5% PharmaResearch is trading at ₩376,000, below its estimated fair value of ₩497,834.15, indicating it may be undervalued based on cash flows. The company forecasts revenue growth of 19.7% annually, surpassing the Korean market's 7.8%. Earnings are expected to grow significantly at 25% per year over the next three years. Recent dividend increases and a strong return on equity forecast further enhance its investment appeal amidst robust financial performance indicators. Our growth report here indicates PharmaResearch may be poised for an improving outlook. Unlock comprehensive insights into our analysis of PharmaResearch stock in this financial health report. Overview: Auras Technology Co., Ltd. manufactures, processes, and retails electronic materials and computer cooling modules across China, Taiwan, Ireland, Singapore, the United States, and internationally with a market cap of NT$45.67 billion. Operations: The company's revenue primarily comes from its Electronic Components & Parts segment, which generated NT$15.78 billion. Estimated Discount To Fair Value: 44.1% Auras Technology, trading at NT$506, is significantly undervalued with an estimated fair value of NT$904.98. It reported a notable earnings growth of 53.6% last year and forecasts revenue to grow at 21.4% annually, outpacing the Taiwan market's 9.5%. Earnings are expected to rise by 28.5% per year over the next three years, despite recent share price volatility, highlighting its potential as an undervalued stock based on cash flows in Asia. Our expertly prepared growth report on Auras Technology implies its future financial outlook may be stronger than recent results. Get an in-depth perspective on Auras Technology's balance sheet by reading our health report here. Overview: Aozora Bank, Ltd., along with its subsidiaries, offers a range of banking products and services both in Japan and internationally, with a market capitalization of ¥272.33 billion. Operations: Aozora Bank, Ltd. generates revenue through its diverse banking products and services offered domestically and internationally. Estimated Discount To Fair Value: 46.6% Aozora Bank is trading at ¥1,968, significantly below its estimated fair value of ¥3,685.05, highlighting its status as undervalued based on cash flows. The bank reported a turnaround with a net income of ¥16.23 billion for the nine months ending December 2024 compared to a loss previously. However, it faces challenges with high bad loans (2.1%) and past shareholder dilution but anticipates profitability growth above market averages over the next three years. Insights from our recent growth report point to a promising forecast for Aozora Bank's business outlook. Take a closer look at Aozora Bank's balance sheet health here in our report. Unlock our comprehensive list of 263 Undervalued Asian Stocks Based On Cash Flows by clicking here. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSDAQ:A214450 TPEX:3324 and TSE:8304. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
29-04-2025
- Business
- Yahoo
Asian Stocks Trading Below Estimated Value In April 2025
As of April 2025, Asian markets are navigating a landscape marked by easing trade tensions and cautious optimism, with China and Japan showing resilience amid global economic uncertainties. In this context, identifying undervalued stocks becomes crucial for investors seeking opportunities in Asia's diverse markets, where potential value can be unlocked through careful analysis of fundamentals and market positioning. Name Current Price Fair Value (Est) Discount (Est) Xiamen Amoytop Biotech (SHSE:688278) CN¥74.29 CN¥144.77 48.7% BYD Electronic (International) (SEHK:285) HK$31.80 HK$63.03 49.5% Alexander Marine (TWSE:8478) NT$142.50 NT$280.32 49.2% Zhende Medical (SHSE:603301) CN¥19.33 CN¥37.64 48.6% Members (TSE:2130) ¥1137.00 ¥2211.77 48.6% Rakus (TSE:3923) ¥2194.50 ¥4296.95 48.9% Beijing Zhong Ke San Huan High-Tech (SZSE:000970) CN¥10.51 CN¥20.78 49.4% BalnibarbiLtd (TSE:3418) ¥1152.00 ¥2223.40 48.2% Swire Properties (SEHK:1972) HK$16.82 HK$32.75 48.6% Yuhan (KOSE:A000100) ₩113000.00 ₩219128.89 48.4% Click here to see the full list of 263 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Here we highlight a subset of our preferred stocks from the screener. Overview: PharmaResearch Co., Ltd., along with its subsidiaries, is a biopharmaceutical company operating mainly in South Korea, with a market capitalization of approximately ₩3.91 trillion. Operations: The company generates revenue primarily from its Pharmaceuticals segment, amounting to approximately ₩350.12 billion. Estimated Discount To Fair Value: 24.5% PharmaResearch is trading at ₩376,000, below its estimated fair value of ₩497,834.15, indicating it may be undervalued based on cash flows. The company forecasts revenue growth of 19.7% annually, surpassing the Korean market's 7.8%. Earnings are expected to grow significantly at 25% per year over the next three years. Recent dividend increases and a strong return on equity forecast further enhance its investment appeal amidst robust financial performance indicators. Our growth report here indicates PharmaResearch may be poised for an improving outlook. Unlock comprehensive insights into our analysis of PharmaResearch stock in this financial health report. Overview: Auras Technology Co., Ltd. manufactures, processes, and retails electronic materials and computer cooling modules across China, Taiwan, Ireland, Singapore, the United States, and internationally with a market cap of NT$45.67 billion. Operations: The company's revenue primarily comes from its Electronic Components & Parts segment, which generated NT$15.78 billion. Estimated Discount To Fair Value: 44.1% Auras Technology, trading at NT$506, is significantly undervalued with an estimated fair value of NT$904.98. It reported a notable earnings growth of 53.6% last year and forecasts revenue to grow at 21.4% annually, outpacing the Taiwan market's 9.5%. Earnings are expected to rise by 28.5% per year over the next three years, despite recent share price volatility, highlighting its potential as an undervalued stock based on cash flows in Asia. Our expertly prepared growth report on Auras Technology implies its future financial outlook may be stronger than recent results. Get an in-depth perspective on Auras Technology's balance sheet by reading our health report here. Overview: Aozora Bank, Ltd., along with its subsidiaries, offers a range of banking products and services both in Japan and internationally, with a market capitalization of ¥272.33 billion. Operations: Aozora Bank, Ltd. generates revenue through its diverse banking products and services offered domestically and internationally. Estimated Discount To Fair Value: 46.6% Aozora Bank is trading at ¥1,968, significantly below its estimated fair value of ¥3,685.05, highlighting its status as undervalued based on cash flows. The bank reported a turnaround with a net income of ¥16.23 billion for the nine months ending December 2024 compared to a loss previously. However, it faces challenges with high bad loans (2.1%) and past shareholder dilution but anticipates profitability growth above market averages over the next three years. Insights from our recent growth report point to a promising forecast for Aozora Bank's business outlook. Take a closer look at Aozora Bank's balance sheet health here in our report. Unlock our comprehensive list of 263 Undervalued Asian Stocks Based On Cash Flows by clicking here. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSDAQ:A214450 TPEX:3324 and TSE:8304. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
28-04-2025
- Business
- Yahoo
3 Asian Stocks Estimated To Be Up To 41.2% Below Their Intrinsic Value
As trade tensions between the U.S. and China show signs of easing, Asian markets are experiencing a cautious optimism that could influence investment opportunities in the region. In this environment, identifying undervalued stocks becomes crucial for investors looking to capitalize on potential market corrections or shifts, as these stocks may offer significant upside if their intrinsic values are realized amidst improving economic conditions. Name Current Price Fair Value (Est) Discount (Est) Xiamen Amoytop Biotech (SHSE:688278) CN¥74.29 CN¥144.77 48.7% BYD Electronic (International) (SEHK:285) HK$31.80 HK$63.03 49.5% Alexander Marine (TWSE:8478) NT$142.50 NT$280.32 49.2% Zhende Medical (SHSE:603301) CN¥19.33 CN¥37.64 48.6% Members (TSE:2130) ¥1137.00 ¥2211.77 48.6% Rakus (TSE:3923) ¥2194.50 ¥4296.95 48.9% Beijing Zhong Ke San Huan High-Tech (SZSE:000970) CN¥10.51 CN¥20.78 49.4% BalnibarbiLtd (TSE:3418) ¥1152.00 ¥2223.40 48.2% Swire Properties (SEHK:1972) HK$16.82 HK$32.75 48.6% Yuhan (KOSE:A000100) ₩113000.00 ₩219128.89 48.4% Click here to see the full list of 263 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Let's review some notable picks from our screened stocks. Overview: NCSOFT Corporation develops and publishes online games worldwide, with a market cap of ₩2.86 trillion. Operations: The company generates revenue of ₩1.58 trillion from its online games and game services segment. Estimated Discount To Fair Value: 41.2% NCSOFT is trading at ₩150,700, significantly below its estimated fair value of ₩256,089.25, suggesting it may be undervalued based on cash flows. Despite a challenging year with declining sales and net income from KRW 1.78 trillion to KRW 1.58 trillion and KRW 212 billion to KRW 94 billion respectively, earnings are forecasted to grow significantly at 24.86% annually over the next three years, outpacing the Korean market's growth rate of 21.5%. According our earnings growth report, there's an indication that NCSOFT might be ready to expand. Delve into the full analysis health report here for a deeper understanding of NCSOFT. Overview: Bosideng International Holdings Limited operates in the apparel industry in the People's Republic of China with a market cap of HK$47.05 billion. Operations: The company's revenue segments include Down Apparels at CN¥20.66 billion, Ladieswear Apparels at CN¥735.22 million, Diversified Apparels at CN¥254.12 million, and Original Equipment Manufacturing (OEM) Management at CN¥2.97 billion. Estimated Discount To Fair Value: 30.6% Bosideng International Holdings is trading at HK$4.11, well below its estimated fair value of HK$5.92, indicating potential undervaluation based on cash flows. Despite an unstable dividend history, the company's earnings are projected to grow at 13.21% annually, surpassing the Hong Kong market's growth rate of 10.6%. Recent shareholder meetings focused on future transaction renewals and annual caps could impact strategic directions and financial outlooks positively in the long term. Our earnings growth report unveils the potential for significant increases in Bosideng International Holdings' future results. Get an in-depth perspective on Bosideng International Holdings' balance sheet by reading our health report here. Overview: YanKer shop Food Co., Ltd is involved in the research, development, production, and sale of leisure food products both in China and internationally, with a market cap of CN¥24.24 billion. Operations: YanKer shop Food Co., Ltd generates revenue through its core activities of researching, developing, producing, and selling leisure food products domestically and abroad. Estimated Discount To Fair Value: 10.1% YanKer shop Food Ltd is trading at CNY 88.88, slightly below its estimated fair value of CNY 98.9, suggesting potential undervaluation based on cash flows. The company reported significant earnings growth of 18.9% last year and forecasts a further increase of 22.69% annually over the next three years, although this lags behind the Chinese market's average growth rate. Recent earnings reports show robust revenue increases, yet dividends remain inadequately supported by free cash flows. The growth report we've compiled suggests that YanKer shop FoodLtd's future prospects could be on the up. Dive into the specifics of YanKer shop FoodLtd here with our thorough financial health report. Investigate our full lineup of 263 Undervalued Asian Stocks Based On Cash Flows right here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A036570 SEHK:3998 and SZSE:002847. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
28-04-2025
- Business
- Yahoo
Asian Stocks With Estimated Discounts Up To 48% That May Offer Value
As trade tensions between the U.S. and China show signs of easing, Asian markets have experienced a boost in investor sentiment, with indices like Japan's Nikkei 225 and China's Shanghai Composite seeing gains. In this environment, identifying undervalued stocks can be particularly rewarding as these equities may offer potential value when the market stabilizes further. Top 10 Undervalued Stocks Based On Cash Flows In Asia Name Current Price Fair Value (Est) Discount (Est) Xiamen Amoytop Biotech (SHSE:688278) CN¥74.76 CN¥144.95 48.4% Pegasus (TSE:6262) ¥473.00 ¥915.75 48.3% Alexander Marine (TWSE:8478) NT$141.00 NT$279.84 49.6% Micro-Star International (TWSE:2377) NT$136.50 NT$265.25 48.5% Tongqinglou Catering (SHSE:605108) CN¥20.99 CN¥41.22 49.1% World Fitness Services (TWSE:2762) NT$80.30 NT$155.61 48.4% Wenzhou Yihua Connector (SZSE:002897) CN¥39.00 CN¥77.30 49.6% giftee (TSE:4449) ¥1522.00 ¥2977.64 48.9% Swire Properties (SEHK:1972) HK$16.50 HK$32.60 49.4% Visional (TSE:4194) ¥8421.00 ¥16492.53 48.9% Click here to see the full list of 256 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Here we highlight a subset of our preferred stocks from the screener. Overview: Xiamen Tungsten Co.,Ltd. operates in China, focusing on the sale of tungsten, molybdenum, rare earth, and new energy materials with a market cap of CN¥30.04 billion. Operations: The company's revenue is derived from the sale of tungsten, molybdenum, rare earth, and new energy materials within China. Estimated Discount To Fair Value: 42.2% Xiamen Tungsten Ltd. appears undervalued, trading 42.2% below its estimated fair value of CNY 32.72, with a current price of CNY 18.92. Despite a recent dip in net income to CNY 391 million for Q1 2025, earnings are forecast to grow significantly at 25.8% annually, outpacing the Chinese market average growth rate. However, potential investors should note its unstable dividend track record despite strong cash flow indicators and growth forecasts. SHSE:600549 Discounted Cash Flow as at Apr 2025 Overview: Ningbo Sanxing Medical Electric Co., Ltd. manufactures and sells power distribution and utilization systems in China and internationally, with a market cap of CN¥36.99 billion. Operations: The company's revenue segments include the manufacturing and sale of power distribution and utilization systems both domestically and internationally.
